MGMT and glioma: As shown in Figure 6B, higher risk scores were significantly associated with older age, higher WHO grades, IDH wildtype mutation status, absence of 1p/19q co-deletion, MGMT unmethylated status, and chemotherapy-treated glioma patients, while risk scores were not associated with sex or radiotherapy status.